AstraZeneca and Daiichi Sankyo Secure Earlier‑Line Enhertu Approvals in South Korea

Why It Matters

The Korean approvals expand Enhertu’s therapeutic reach beyond later‑line settings, potentially accelerating revenue growth for AstraZeneca and Daiichi Sankyo in a market where HER2‑positive gastric cancer remains a major health burden. By demonstrating superior efficacy over established regimens, the data may influence treatment guidelines worldwide and encourage faster adoption of antibody‑drug conjugates in earlier disease stages. The move also underscores the importance of Asian regulatory pathways in shaping global oncology strategies. Furthermore, the approvals highlight the balancing act between efficacy and safety, as ILD remains a notable adverse event. Successful management of this risk will be crucial for broader acceptance and could set a precedent for how regulators evaluate ADCs with similar toxicity profiles.

Key Takeaways

• AstraZeneca and Daiichi Sankyo received MFDS approval for first‑line metastatic HER2‑positive breast cancer and second‑line HER2‑positive gastric cancer in South Korea.
• DESTINY‑Breast09 showed a 44 % reduction in progression or death, with median PFS of 40.7 months versus 26.9 months for THP.
• DESTINY‑Gastric04 demonstrated a 30 % mortality risk reduction, extending median OS to 14.7 months versus 11.4 months.
• Interstitial lung disease occurred in 12.1 % (breast) and 13.9 % (gastric) of patients, mostly grade 1‑2.
• The approvals position Enhertu to capture a larger share of Korea’s oncology market and may prompt similar moves in other Asian jurisdictions.

Pulse Analysis

Enhertu’s leap into earlier‑line therapy in South Korea reflects a broader shift toward antibody‑drug conjugates as front‑line options in HER2‑positive cancers. Historically, the HER2 space has been dominated by trastuzumab‑based combinations, but the robust PFS and OS gains reported in DESTINY‑Breast09 and DESTINY‑Gastric04 suggest that the ADC’s payload delivers a meaningful advantage. The Korean regulator’s willingness to endorse these data, despite the ILD signal, indicates a growing tolerance for manageable toxicities when efficacy is compelling.

From a commercial perspective, the Korean market serves as a bellwether for other high‑incidence Asian economies. If clinicians adopt Enhertu early, the drug could quickly become a revenue engine, offsetting the higher development costs associated with ADC technology. Moreover, the approvals may catalyze parallel submissions in Japan, China, and Taiwan, where HER2‑positive gastric cancer prevalence is similarly high. Competitors such as Roche’s Kadcyla and newer ADCs from AbbVie and Pfizer will now face a more aggressive market environment, potentially accelerating their own pipeline timelines.

Looking ahead, the key challenge will be post‑marketing surveillance of ILD. Real‑world data will determine whether the low‑grade nature observed in trials translates to routine practice. Successful risk‑mitigation strategies could set a new standard for ADC safety monitoring, influencing future regulatory decisions worldwide. In sum, the Korean approvals not only broaden Enhertu’s label but also signal a turning point in how HER2‑targeted therapies are sequenced, with implications that could reshape global oncology treatment algorithms.